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AbstrAct:
Gene-based anticancer therapies delivered by adenoviruses are limited by the 
poor viral distribution into the tumor. In the current work we have explored the 
feasibility of targeting pancreatic tumors through a loco-regional route. 
We have taken advantage of the ductal network in the pancreas to retrogradelly 
inject adenoviruses through the common bile duct in two different mouse models of 
pancreatic carcinogenesis: The transgenic Ela-myc mice that develop mixed neoplasms 
displaying both acinar-like and duct-like neoplastic cells affecting the whole pancreas; 
and mice bearing PANC-1 and BxPC-3 orthotopic xenografts that constitute a model 
of localized human neoplastic tumors. We studied tumor targeting and the anticancer 
effects of newly thymidine kinase-engineered adenoviruses both in vitro and in vivo, 
and conducted comparative studies between intraductal or intravenous administration. 
Our data indicate that the intraductal delivery of adenovirus efficiently targets 
pancreatic tumors in the two mouse models. The in vivo application of AduPARTKT plus 
ganciclovir (GCV) treatment induced tumor regression in Ela-myc mice. Moreover, the 
intraductal injection of ICOVIR15-TKT oncolytic adenoviruses significantly improved 
mean survival of mice bearing PANC-1 and BxPC-3 pancreatic xenografts from 30 to 
52 days and from 20 to 68 days respectively (p<0.0001) when combined with GCV. 
Of notice, both AduPARTKT and ICOVIR15-TKT antitumoral responses were stronger 
by ductal viral application than intravenously, in line with the 38-fold increase in 
pancreas transduction observed upon ductal administration. 
In summary our data show that cytotoxic adenoviruses retrogradelly injected to 
the pancreas can be a feasible approach to treat localized pancreatic tumors.
INtrODUctION
Pancreatic ductal adenocarcinoma (PDAC) is the 
predominant form of pancreatic cancer and is one of the 
most aggressive and devastating human malignancies 
in developed countries. It is the fourth leading cause of 
cancer related deaths and has an extremely poor prognosis, 
with a median survival of 6 months and a 5-year survival 
of less than 5%. Pancreatic cancer is usually diagnosed 
at late stages and only 10-15% of patients present with 
operable disease. About 25% of unresectable PDACs 
are locally advanced and the rest are metastatic. The 
only potentially curative treatment is complete surgical 
resection of the tumor. Currently, the survival of non-
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resected patients is not fundamentally altered by any 
particular general therapy [1]. 
Gene therapy and virotherapy represent promising 
new therapeutic modalities for cancer. Among them, 
oncolytic adenoviruses are at the front line of anticancer 
agents. They are engineered to specifically target, 
replicate in and destroy cancer cells [2-4]. The possibility 
to arm the viruses with transgenes has resulted in 
improved antitumoral agents. However, the efficacy 
of these therapies is highly dependent on the capacity 
of adenoviruses to enter tumor cells and to distribute 
throughout the tumor. Commonly, they are applied in 
vivo through intratumoral injections or by systemic 
delivery. However, both intratumoral and intravenous 
administrations result in reduced spread of the viruses 
throughout the tumor limiting their therapeutic impact [5].
The exocrine pancreas is a secretory organ from 
which cells release digestive enzymes or ions through 
a complex network of ducts.  Such network is well 
organized in a ductal tree that branches from the main 
duct to small interlobular ducts, generating intralobular 
and intercalated ducts [6]. In the present study we have 
taken advantage of such ductal network to address the 
feasibility to target pancreatic tumors by the retrograde 
delivery of adenoviruses into the common bile duct. 
This technique is similar to the endoscopic retrograde 
cholangiopancreatography, which has been established 
as a safe procedure in humans [7] and previous studies 
have shown that adenovirus and adeno-associated virus 
can be efficiently delivered to the mouse pancreas by 
this approach [8, 9]. We have analyzed adenoviral tumor 
targeting in the transgenic Ela-myc mouse model of 
pancreatic tumorogenesis and in pancreatic orthotopic 
xenografts. Ela-myc mice express oncogene c-myc under 
the elastase promoter and develop mixed acinar-ductal 
tumors in a ductal architecture that resembles PDAC [10, 
11] which makes them an interesting model to evaluate 
the potential of the intraductal delivery route; however, 
the study of adenoviral therapies is limited to the use of 
recombinant adenovirus because mouse cells are poorly 
permissive to human adenovirus replication [12]. Thus, 
to evaluate the potential therapeutic value of oncolytic 
adenoviruses when applied intraductally, human orthotopic 
xenografts have been used as a model. Antitumoral effects 
have been evaluated by administering TK-engineered 
adenoviruses: the recombinant AduPARTKT and the 
oncolytic adenovirus ICOVIR15-TKT. Our data shows 
that intraductal administration is an effective delivery 
route to target tumors with adenoviruses and ICOVIR15-
TKT is a potent oncolytic adenovirus that provides with 
antitumor efficacy when combined with GCV. Noticeable 
significantly enhanced anticancer effects were obtained, 
upon intraductal administration compared to systemic 
injection. We propose the intraductal delivery as a novel 
route to administer adenoviruses to pancreatic cancer 
patients.
rEsULts
Intraductal delivery of reporter adenoviruses 
targets pancreatic tumors in transgenic Ela-myc 
mice
AdCMVGFPLuc reporter adenovirus was injected 
into the common bile duct of 11-weeks-old transgenic Ela-
myc and wild type (wt) mice. At this age all transgenic 
mice exhibited acinar neoplasms and 77% displayed a 
mixed acinar-ductal phenotype with tumor nodules ranging 
from 2-7 mm in diameter (Supplementary Fig. S1) [10]. 
Bioluminiscence imaging revealed luciferase expression 
restricted to the pancreas (Fig. 1A). Quantification 
of luciferase activity in tissue extracts showed higher 
activity in the pancreas of wt animals at all the time-points 
analyzed, that peaked at day 4 in both wt and Ela-myc 
mice (Fig. 1B). To enhance tumor selectivity AduPARLuc 
adenovirus was intraductally injected, previous data from 
our group has shown that AduPARLuc was highly active 
in tumor cells with reduced expression in normal tissue 
[13]. Taking advantage of the double cassette (CMVp/
GFP and uPARp/Luc) in the AduPARluc virus, in the 
current study we show that AduPARLuc intraductally 
administered, broadly reaches the pancreas (strong 
GFP immunoreactivity) while uPAR promoter limits 
luciferase expression (weak luciferase signal) in normal 
pancreas (Fig. 1C, left panel). In line with these results, 
luciferase activity in the AduPARLuc injected pancreas 
was 2-log reduced when compared to AdCMVGFPLuc 
(Fig. 1C, right panel). Pancreatic tumor selectivity was 
confirmed in AduPARLuc injected animals showing a 
significantly higher (8,34-fold, p=0.016) cancer-specific 
index (established as a tumor to pancreas ratio) (Fig. 1D). 
This was in line with the observation that the uPAR gene 
was highly expressed in Ela-myc tumors (Supplementary 
Fig. S2). High intratumoral activity of uPAR controlled 
adenovirus was also evident from the analysis of anti-
luciferase immunohistochemistry in Ela-myc tumors 
intraductally injected with AduPARLuc. Strong positive 
staining of acinar hyperplasic regions (Fig. 1E, left panel) 
and extensive areas of ductal-like tumor masses with dense 
stroma were observed (Fig. 1E, middle and right panels). 
Intraductally delivered AduPArtKt adenovirus 
followed by GcV treatment triggers an 
antitumoral response in Ela-myc mice
To evaluate the potential of adenoviral-based 
therapies to induce antitumoral effects upon application of 
this newly proposed route of virus administration, first we 
generated recombinant adenovirus expressing a modified 
form of the TK gene (TKT) under the control of the uPAR 
Oncotarget 2013; 4: 94-10596www.impactjournals.com/oncotarget
promoter (AduPARTKT). To examine the cytotoxic effects 
of the AduPARTKT/GCV suicide gene therapy, we first 
established Emyc cell lines from Ela-myc pancreatic 
tumors. These cell lines expressed ductal markers as well 
as the uPAR gene and were susceptible to adenoviral 
transduction (Supplementary Fig. S3). Cytotoxic 
evaluation of AduPARTKT/GCV was performed in Emyc 
cells and compared to BxPC-3 and PANC-1 human 
Figure 1: Expression of reporter adenoviruses intraductally administered into the common bile duct of wt and 
Ela-myc mice. A, 5x1010 vp of AdCMVGFPLuc were intraductally administered to wt (n=7) or Ela-myc (n=9) mice and luciferase 
expression was measured four days later. (K: kidney, D: diafragm, L: liver, St: stomach, Sp: spleen, I: intestine and P: pancreas). B, 1010 
vp of AdCMVGFPLuc were intraductally administered to wt (n=5) and Ela-myc mice (n=5), and luciferase expression was measured in 
pancreatic tissue extracts. C, D, 1010 vp of AdCMVGFPLuc or AduPARLuc were intraductally administered to wt (n=7 and 5, respectively) 
and Ela-myc mice (n=5); expression studies were performed 4 days later. C. Anti-GFP and anti-luciferase IHC in the pancreas of wt mice 
injected with AduPARLuc (left panel). Luciferase activity in the pancreas of wt mice (right panel). D. Cancer-specific index for each virus 
is expressed as the luciferase ratio tumor-pancreas (Ela-myc pancreas/ wt pancreas). E, Anti-luciferase IHC and H&E staining of pancreatic 
tissue sections from Ela-myc mice four days after i.d administration of AduPARLuc (1010 vp). Scale bars: 400 µm, 200 µm and 100 µm 
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pancreatic cancer cells. To this end cells were transduced 
with increasing doses of AduPARTKT and cell viability 
was analyzed after 3 days in culture in the presence of the 
prodrug GCV. MTT assays showed that the AduPARTKT/
GCV treatment was able to induce cytotoxicity in Emyc 
cells to a larger extent than in PANC-1 or BxPC-3 cells, as 
evidenced by a shift to the left in the dose-response curve 
and by displaying the lowest ID50 value, indicating higher 
sensitivity to the treatment (Fig. 2A). To further analyze 
the cytotoxicity of the AduPARTKT/GCV system in 
Emyc cells, we evaluated for the presence of a bystander 
effect and compared it to that of PANC-1 cells, a cell line 
reported to have a moderate TK/GCV bystander effect 
[14]. Cells were transduced with AdTK at a viral dose 
corresponding to its ID90, and designated as TK
+ positive 
cells. Cocultures of 50% TK+ and 50% TK- cells were 
established at high confluence and treated with GCV for 3 
days. Under these conditions the presence of a bystander 
effect would be detected when viability reached values 
below 55%. MTT analysis revealed that the survival of 
the Emyc-3 cocultures (15%) was significantly lower than 
that of PANC-1 (28%) (Fig. 2B, left panel). The enhanced 
effect in Emyc-3 cells could be, at least partially explained 
by the expression of connexin-43, a well-known mediator 
of the TK/GCV bystander effect (Fig. 2B, right panel) 
[14]. 
To analyze whether the cytotoxic effects of 
AduPARTKT/GCV would translate into an antitumor 
response, 11-weeks-old Ela-myc mice were randomly 
distributed into five groups. Mice received intraductal 
injections of PBS, AduPARTKT (5x1010 vp) or 
AduPARTKT (1011vp); three days later, when stated, a 
daily dose of GCV (100 mg/Kg) was administered for 
6 consecutive days and six weeks after viral injection 
antitumor effects were determined. Given the fact that 
at 17-weeks of age the whole pancreas of Ela-myc mice 
displays carcinogenic lesions, the measure of pancreatic 
volume was used as an indicator of treatment effects. 
The three control groups that received PBS, GCV or 
AduPARTKT alone showed large pancreatic volumes (1.8-
fold over the pancreas of wild type mice). By contrast, 
animals treated with AduPARTKT and GCV presented 
pancreatic volumes significantly smaller and similar to 
those of wild type animals. No differences were observed 
between the two viral doses (Fig. 2C). Of note, in a group 
of mice, tumor nodules observed at surgery completely 
regressed by treatment. 
We reasoned that the presence of a large tumor in 
the pancreas could alter normal pancreatic function. In 
this line we assessed the levels of the pancreatic enzymes 
amylase and lipase in the serum of untreated Ela-myc 
mice. At 12-weeks of age Ela-myc mice already presented 
amylase levels above the reference range that dramatically 
increased by week 17. Lipase activity gradually increased 
over-time, reaching a 2.7-fold increase on the reference 
values by week 17 (Fig. 2D). Interestingly, AduPARTKT/
Figure 2: Antitumoral effects of AduPArtKt/GcV 
in pancreatic cancer cell lines and in Ela-myc mice. 
A, Dose-response analysis of AduPARTKT/GCV treatment 
in PANC-1, BxPC-3 and Emyc-3 cells. B, Left: TK/GCV 
bystander effect assessed on 1:1 cocultures of TK+/TK- cells. 
Right: Connexin 43 expression analyses. C, Antitumoral effect 
of AduPARTKT/GCV therapy upon intraductal administration 
of the virus to Ela-myc mice followed by 6 doses of GCV. 
Pancreatic volume at six weeks after virus administration is 
plotted as indicator of antitumor effect. Dashed line corresponds 
to the pancreatic volume of wt mice (n=8). D, Analysis of 
amylase and lipase serum levels in non-treated (n=5) and treated 
Ela-myc mice (n=5). Dashed lines indicate reference values 
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GCV treatment resulted in normalization of the serum 
pancreatic enzymes (Fig. 2D).  
These findings reveal that the intraductal delivery of 
AduPARTKT followed by GCV reduces tumor progression 
and ameliorates pancreatic dysfunction in Ela-myc mice.
Intraductal delivery of IcOVIr15-tKt targets 
pancreatic tumors in orthotopic xenografts and 
increases mice survival 
To further validate the potential of intraductal 
delivery of cytotoxic adenoviruses as a therapeutic route 
for cancer treatment, we sought to study the potential 
antitumor effects of oncolytic viruses in pancreatic 
xenografts. We have previously shown that oncolytic 
adenoviruses expressing the TK gene when combined 
with GCV present enhanced antitumoral response and 
can be traced in vivo by PET imaging [15]. However, the 
limited genome encapsidation capacity of adenoviruses 
results in packaging problems when the TK gene is 
inserted. Interestingly a constrained genome size in an 
ICOVIR-15 backbone has been reported to allow for 
efficient transgene expression and oncolytic potency 
[16]. In this regard, we generated the ICOVIR15-TKT by 
inserting the TK gene into the ICOVIR15 genome (Fig. 
3A). Tumor selectivity of ICOVIR-15 was achieved by 
inserting eight E2F-binding sites and one Sp1-binding 
site in the E1A endogenous promoter. The TK gene was 
inserted downstream of the fiber gene under the control of 
the Major Late Promoter as previously reported [17]. The 
oncolytic potency of ICOVIR15-TKT plus GCV was first 
Figure 3: Antitumoral effects of IcOVIr15-tKt/GcV in pancreatic cancer cell lines and in human orthotopic tumors. 
A, Schematic representation of ICOVIR15-TKT virus. B, Dose-response analysis of ICOVIR15, ICOVIR15-TKT and ICOVIR15-TKT 
plus GCV in PANC-1-Luc and BxPC-3-Luc cells. C, Anti-E1A immunofluorescence of BxPC-3-Luc tumors, at 3 days after intraductal 
administration of ICOVIR15-TKT (5x1010 vp). Scale bar: 100 µm. D, Antitumoral effect of ICOVIR15-TKT/GCV therapy upon intraductal 
administration of virus to mice bearing PANC-1-Luc and BxPC-3-Luc orthotopic pancreatic tumors. Kaplan-Meier analysis survival curves 
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studied in vitro and compared to ICOVIR15-TKT without 
GCV and to the parental oncolytic virus ICOVIR-15. The 
cell killing effect was lower in PANC-1-Luc and BxPC-
3-Luc cell cultures when infected with ICOVIR15-TKT 
adenovirus, however the addition of GCV led to enhanced 
cytotoxicity. BxPC-3-Luc cells were more sensitive than 
PANC-1-Luc cells both to adenoviral cell killing and to 
TK/GCV cytotoxicity (Fig. 3B).
Next we assessed the capacity of oncolytic 
adenoviruses to target pancreatic tumors upon intraductal 
administration. To this end, 5x1010 vp of ICOVIR15-TKT 
were intraductally injected into mice bearing BxPC-3-Luc 
Figure 4: comparative study of intraductal and intravenous delivery routes. A, 5x1010 vp of AdCMVGFPLuc were 
intravenously or intraductally administered to wt (n=7 per group) and Ela-myc mice (n=7 per group). Luciferase expression was measured 
four days later. Top panel: Representative bioluminescent images. Bottom panel: Quantification of luciferase expression from captured 
bioluminescence images. B, Ratio pancreas/liver from Ela-myc mice. C, Antitumoral effect of AduPARTKT/GCV therapy upon intraductal or 
intravenous administration of AduPARTKT (5x1010 vp) to Ela-myc mice. Pancreatic volume at six weeks after virus administration is plotted 
as indicator of antitumor effect. D, Antitumoral effect of ICOVIR15-TKT/GCV therapy upon intraductal or intravenous administration of 
ICOVIR15-TKT (5x1010 vp) to mice bearing BxPC-3-Luc orthotopic pancreatic tumors. Tumor growth curves and Kaplan-Meier survival 






























Days after virus administration Days after virus administration
Oncotarget 2013; 4: 94-105100www.impactjournals.com/oncotarget
tumors in the pancreas and E1A expression was evaluated 
in tumor sections. Strong E1A immunoreactivity was 
detected throughout the tumor (Fig. 3C). The antitumoral 
efficacy of ICOVIR15-TKT was studied in the presence 
and the absence of GCV and compared to that of the 
parental oncolytic virus ICOVIR-15. Pancreatic xenograts 
from PANC-1-Luc and BxPC-3-Luc cells were treated 
with a single dose of saline, ICOVIR-15 or ICOVIR15-
TKT at 5x1010 vp/mouse administered intraductally. Mice 
injected with ICOVIR15-TKT were split in two groups, 
one receiving intraperitoneal GCV (100 mg/Kg) at the 
time points indicated in the scheme, while the other 
group received saline solution (Fig. 3D). Treatment with 
ICOVIR-15 and ICOVIR15-TKT improved survival in the 
two xenograft models. Interestingly an enhanced effect 
was observed with the combined treatment of ICOVIR15-
TKT+GCV. Median overall survival increased from 30 
days to 35 for ICOVIR15-TKT; to 42 for ICOVIR-15 
and to 52 for ICOVIR15-TKT+GCV in the PANC-1-
Luc model. Similarly, in the BxPC-3-Luc model overall 
survival increased from 20 days for untreated mice to 
29 for ICOVIR15-TKT; 30 for ICOVIR-15 and to 68 for 
ICOVIR15-TKT+ GCV (Fig. 3D). Thus, the ICOVIR15-
TKT in combination with GCV resulted the most effective 
treatment in the two pancreatic xenograft models.
Intraductal delivery of cytotoxic adenoviruses 
triggers a significantly higher antitumoral 
response than intravenous administration
Anticancer adenoviral based therapies are often 
applied through intravenous delivery. This route of 
administration is necessary to target disseminated cancer, 
however its hepatotoxic related effects encourage the use 
of alternative routes for the treatment of localized tumors. 
We sought to perform a comparative study between 
the intraductal (i.d) and intravenous (i.v) delivery of 
adenoviruses and assess tumor targeting efficiency and 
therapeutic response. First, 5x 1010 viral particles of 
AdCMVGFPLuc were injected into the tail vein or the 
common bile duct of wild type and Ela-myc mice. Four 
days later animals were sacrificed and bioluminescence 
was measured and quantified in the pancreas and the liver 
of injected animals. As shown in figure 4A following 
intravenous injection the strongest signal was detected in 
the liver at similar levels in both wild type and Ela-myc 
mice, whereas lower luciferase expression was detected 
in the pancreas. On the contrary, intraductal injection 
resulted in elevated luciferase activity in the pancreas 
and much lower values were detected in the liver (Fig. 
4A). Noticeably, adenoviruses reached the pancreas both 
in wt and Ela-myc mice more efficiently upon intraductal 
delivery than following intravenous injection (38-fold 
and 5-fold respectively). Moreover, in Ela-myc mice the 
pancreas to liver ratio was significantly higher following 
intraductal delivery suggesting that adenoviruses reached 
more efficiently pancreatic tumors (Fig. 4B). Furthermore 
the enhanced tumor/liver ratio is an indication that through 
this route adenoviral-induced liver damage effects could 
be minimized.
To compare the antitumor efficacy of cytotoxic 
adenoviruses following intravenous or intraductal 
administration, AduPARTKT were injected i.v. or i.d to 
Ela-myc mice and 3 days later they received GCV for 
six consecutive days. Six weeks after viral administration 
mice were sacrificed and the pancreatic volume was 
measured. Saline injected animals presented a large 
pancreas, indicative of tumor progression, whereas 
both i.v. and i.d injected mice showed reduced volume 
demonstrating antitumor efficacy. The major effect was 
observed in mice that received the virus intraductally (Fig. 
4C). 
To further determine the therapeutic potential of 
i.d. delivery, antitumor efficacy was also evaluated by 
applying 5x 1010 vp of oncolytic ICOVIR15-TKT i.v. or 
i.d followed by GCV treatment in BxPC-3-Luc pancreatic 
xenografts, as scheduled in Fig. 3D. Tumor progression 
was analyzed by measuring luciferase expression. An 
exponential increase in luciferase activity was detected 
in the control group. By contrast, ICOVIR15-TKT i.v 
delivered showed a slight increase on luciferase activity 
over time indicating limited tumor growth; interestingly 
the intraductal delivery of ICOVIR15-TKT resulted 
in similar luciferase activity at all the time-points 
analyzed indicative of no tumor growth (Fig. 4D, left 
panel). Furthermore, ICOVIR15-TKT+GCV prolonged 
mouse survival after both intravenous and intraductal 
administration, although a remarkable increased survival 
was observed through intraductal delivery. The median 
survival in mice bearing BxPC3-Luc tumors was of 20 
days for the mock group and of 38 days for the i.v. treated 
group and of 68 days for the i.d. treated group (Fig. 4D, 
right panel).
In summary, these results indicate that the 
intraductal delivery of adenoviruses is more successful 
than the intravenous delivery to target pancreatic tumors 
and induces stronger antitumoral effects.
DIscUssION
One of the major hurdles to meaningful treatment 
of pancreatic ductal adenocarcinoma by adenoviral-based 
therapies, is their relatively limited ability to spread 
throughout the tumor. In the present study we have 
explored the feasibility to achieve antitumoral effects by 
delivering adenoviruses by retrograde injection into the 
common bile duct with the aim to spread the virus into 
the tumor throughout the complex network of pancreatic 
ducts. We have tested this strategy in two different 
experimental models of pancreatic tumorogenesis, the 
transgenic Ela-myc mice that develop autochthonous 
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tumors in the pancreas and a human cell transplantation 
model of orthotopic pancreatic xenografts. Our results 
show that in both models adenovirus, when delivered 
intraductally, are able to target the tumors generated in 
the pancreas as it can be visualized by the expression of 
luciferase in the pancreatic tumor nodules of transgenic 
mice and the immunodetection of E1A protein in the 
xenografted tumors. It has been proposed that tumor cells 
arising in situ in the native organ are distinct from cells 
engrafted into an immunocompromised mouse [18]. In this 
regard, tumors generated in the transgenic mice provide a 
more adequate tumor context for therapeutic evaluation. 
However, mouse cells are not permissive to human 
adenoviral replication thus, the study of antitumor effects 
of therapeutic adenoviruses in transgenic mice upon 
intraductal delivery was limited to the use of recombinant 
adenovirus expressing the suicide gene thymidine kinase 
(AduPARTKT) in combination with GCV. With this 
approach we observed a significant anticancer response 
at the two viral doses tested resulting in a pancreas size at 
week 6 after treatment similar to that of wild type animals, 
whereas control groups doubled the pancreatic mass. 
This good response was probably the result of a good 
sensitivity of the Ela-myc tumor cells to the TK/GCV 
cytotoxicity, as shown in the in vitro data, as well as to the 
spread of the virus into the tumor mass as a consequence 
of the intraductal adenoviral delivery. Furthermore, the 
strong activity of the uPAR promoter in the tumor tissue 
also represents a relevant contributing factor. 
Oncolytic adenoviruses are promising agents for the 
treatment of cancer and the possibility to arm the virus 
with toxic transgenes further provides with enhanced 
potency. The potential of the intraductal delivery as a 
route for pancreatic cancer treatment with oncolytic 
adenoviruses was evaluated in orthotopic xenografts 
models. We have previously shown some of the advantages 
of the combined therapy of adenoviral replication and TK/
GCV cytotoxicity: i) the improvement of the antitumoral 
response under a defined regimen of virus and GCV and 
ii) the possibility to monitor viral activity non-invasively 
by PET imaging based on TK expression [15, 17]. Here 
we report that GCV increases the cellular killing effect 
of the minimal RB responsive-based selective adenovirus 
armed with the TK gene (ICOVIR15-TKT), inducing 
significantly higher antitumor response than the potent 
oncolytic ICOVIR15 upon intraductal delivery in two 
different xenograft models of human pancreatic cancer 
BxPC-3-Luc and PANC-1-Luc. These data are in contrast 
to what is observed in vitro where ICOVIR15 is more 
active than ICOVIR15-TKT. The compromised activity 
of ICOVIR15-TKT might be probably related to the 
limitations that adenoviruses have to efficiently package 
large genomes. ICOVIR15-TKT has a 1.2Kb genome 
larger than ICOVIR15 what makes the virus less efficient 
in replication. The addition of GCV, which triggers the 
cell killing effect mediated by ganciclovir metabolites in 
ICOVIR15-TKT +GCV treated cells fully compensates 
for this effect in BxPC-3-Luc cells, but only partially in 
the PANC-1-Luc model. The differences between cell 
lines may obey to their different sensitivity to cell death 
mediated by oncolysis or through TK/GCV cytotoxicity. 
However in vivo, viral replication does not seem to be 
a limiting factor, probably because there are many other 
tumor barriers that affect similarly to all the viruses. 
Interestingly, in vivo the treatment with ICOVIR15-TKT 
+GCV produces a major antitumoral effect, probably 
because GCV toxic metabolites can spread to non-
infected neighbouring tumoral or stromal cells increasing 
tumor cell destruction [19, 20]. The intraductal delivery 
of ICOVIR15-TKT followed by GCV treatment induced 
a significantly higher antitumoral response than the same 
treatment when the virus was administered systemically. 
The improved anticancer response of intraductal 
compared to intravenous delivery was also observed in 
the AduPARTKT/GCV therapy in transgenic Ela-myc 
mice. This improved response was most probably related 
to an increased presence of adenoviral particles in the 
tumor upon intraductal delivery as suggested by the higher 
expression of luciferase in Ela-myc tumors after reporter 
virus injection. These results suggest that the spreading of 
the viral particles throughout the tumor mass is facilitated 
by the ductal network favoring tumor cell transduction. 
However it is important to note that the presence of the 
tumor stroma might impair a complete antitumor response. 
It is well known that the composition and structure of the 
extracellular matrix (ECM) can slow down the movement 
of molecules within the tumor [21]. In this line it could be 
speculated that the incorporation of an enzymatic agent 
that degrades ECM components could further facilitate 
viral tumor biodistribution and further extend survival. 
Recent reports have shown that the co-administration 
of hyaluronidase and an oncolytic adenovirus or the 
expression of hyaluronidase in an armed oncolytic virus 
improves the spread of the virus throughout the tumor [22, 
23]. The benefits of hyaluronidase as an adjuvant regimen 
has also been shown to enhance gemcitabine anticancer 
effects [24, 25]. Therefore it would be worth to test the 
effects of co-treatment with hyaluronidase in adenoviral 
intraductal administrations.
The injection through the common bile duct or 
intraductal administration employed in the present study 
is an adaptation of the human ERCP technique. Although 
it is considered a safe technique, in around 10% of cases 
leads to a complication of acute pancreatitis which can be 
significantly reduced by administration of indomethacin 
[7, 26]. Transgenic Ela-myc mice already present signs 
of pancreatitis as shown by the elevated serum amylase 
and lipase levels. Although we can not discard that the 
intraductal delivery of adenovirus could induce additional 
pancreatitis at early stages, our data shows that since 
the initial phases of the treatment, AduPARTKT/GCV 
normalizes amylase and lipase serum levels. Another 
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important aspect related to the safety of the delivery route 
is its minimal impact in other organs, as it is demonstrated 
by the higher ratio pancreas/liver achieved upon intraductal 
delivery when compared to intravenous administration in 
transgenic Ela-myc mice. This selectivity could minimize 
the liver-related toxicity associated to adenoviral systemic 
delivery [27].  Another major advantage of the intraductal 
delivery versus systemic administration is the potential 
to apply repeatable administrations. It is well known that 
readministration of an adenovirus of the same serotype is 
not indicated upon systemic delivery because it triggers 
the formation of neutralizing antibodies. Although we 
have not directly evaluated the feasibility of repeated 
administrations, Tominaga and collaborators showed with 
a very similar approach that readministration of adenoviral 
particles into the common bile duct of wild type mice 
resulted in efficient transgene expression without the need 
of any immunosuppressive strategies [28]. 
In summary, we have shown that retrograde 
intraductal adenoviral administration can be a feasible 
approach to efficiently and selectively target pancreatic 
tumors. Moreover the intraductal application of 
AduPARTKT and ICOVIR-15TKT in combination with 
GCV elicits significantly higher antitumor responses than 
the systemic delivery. These data highlight the potential of 
intraductal adenoviral delivery for the treatment of non-
metastatic pancreatic neoplasms. 
MEtHODs 
cell lines 
HEK293 cells and the human pancreatic 
adenocarcinoma cell lines PANC-1, BxPC-3, were 
obtained from the American Type Cancer Collection 
(ATCC). PANC-1-Luc and BxPC-3-Luc were obtained 
and maintained as described previously [13, 29]. Emyc 
cells were established in our laboratory from pancreatic 
tumors of Ela-myc mice as described in Supplementary 
Methods. Cell lines were expanded as previously 
described [30]. Every 2 months, cells were plated  from a 
frozen vial of the original batch but were not authenticated 
by the authors. Interspecies contamination was tested by 
PCR routinely.
Adenovirus construction
Construction of AdCMVGFPLuc, AduPARLuc, 
AdTK and ICOVIR-15 have been previously described 
[3, 13, 16, 31, 32]. AdCMVGFPLuc and AduPARLuc 
express the enhanced GFP gene under the control of 
CMV promoter and the firefly luciferase gene under 
the control of CMV or uPAR promoter, respectively. 
AdTK adenovirus encodes the Herpes Simplex virus 
Thymidine Kinase (HSV-TK) under the control of a CMV 
promoter. In the present work we have generated the 
recombinant adenovirus AduPARTKT and the oncolytic 
virus ICOVIR15-TKT. The AduPARTKT recombinant 
adenovirus was generated by inserting the 1.2 kb sequence 
of the Tat8TK gene, a modified TK with enhanced 
cytotoxicity [33], into the NotI/XhoI sites of the pShuttle 
vector (Stratagene). Next, the SV40 polyA tail was cloned 
into the XhoI/XbaI sites of the previously generated 
plasmid, and the uPAR promoter (450 bp fragment) 
was inserted into the NotI site. Next, homologous 
recombination of the resulting pShuttle vector with the 
adenoviral genome was carried following a standard 
protocol. Viral particles were obtained and propagated in 
HEK293 cells. Oncolytic ICOVIR15-TKT adenovirus was 
constructed by first generating the plasmid pICOVIR15-
TKT. This plasmid was constructed by homologuos 
recombination in Saccharomyces cerevisiae [34] using 
SpeI-digested pICOVIR15 plasmid [16] as acceptor 
vector, and the SalI-PacI right end adenovirus genome 
fragment from plasmid pICOVIR5-TK-L [15] as donor 
insert. pICOIVR15-TKT was cut with PacI and transfected 
in HEK293 cells to generate ICOVIR15-TKT, which was 
plaque isolated and propagated in A549 cells. All viruses 
were purified by standard cesium chloride banding and the 
physical particle concentration (vp/ml) was determined by 
optical density reading (OD260).
Western blot analysis 
Western blots were performed as previously 
described [14] and imaged on a LAS-3000 image analyzer 
(Fuji PhotoFilm Co.). Anti-Connexin43 (MAB3068, 
Chemicon International) and anti-α-tubulin (T9026, 
Sigma-Aldrich) were used as primary antibodies. 
In vitro cytotoxicity assays 
PANC-1, PANC-1-Luc, BxPC-3, BxPC-3-Luc 
and Emyc-3 cells were transduced with AduPARTKT, 
ICOVIR15 or ICOVIR15-TKT viruses, and cultured in 
the presence or absence of GCV (10 mg/ml, Cymevene) 
for 3 or 4 days. Cell viability was measured by an MTT 
colorimetric assay (Roche Molecular Biochemicals). 
ID50 values were estimated from dose-response curves 
by standard non-linear regression, using an adapted Hill 
Equation (Prism, version 5; GraphPad Software).
The TK/GCV bystander effect was measured 
by determining the viability of a mixed cell population 
composed of different percentages of TK+ (100 or 
50%) and TK- (0 or 50%) cells, cultured for 3 days in 
the presence of GCV (10 µg/ml, Cymevene; Roche). 
The TK positive (TK+) cells were generated 24 h before 
establishing the cocultures by transduction with the 
recombinant adenovirus AdTK.
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Mouse models
Animal procedures met the guidelines of European 
Community Directive 86/609/EEC and were approved 
by the Local Ethical Committee. Transgenic Ela-myc 
and wt C57Bl6 mice of 11-17 weeks of age were used. 
Male athymic nu/nu mice (6-8 weeks old, Harlan Iberica) 
were used to generate orthotopic pancreatic tumors. Ela-
myc mice were genotyped by multiplex PCR analysis as 
described in Supplementary Methods. Transgenic mice 
and wild type littermates were used in this study.
PANC-1-Luc and BxPC-3-Luc orthotopic tumors 
were generated by injecting 5x105 cells into the pancreas 
of athymic nude mice, in a final volume of 50 µl, as 
previously described [29]. 
Intraductal injection
Mice were anesthetized with a mixture of 
isofluorane and oxygen, and a mixture of buprenorphine 
(0.1 mg/Kg) and meloxicam (2 mg/Kg) was used as 
analgesic. A laparotomy of 2 cm was performed through 
a midline abdominal incision. Then the duodenum was 
exposed and the common bile duct was clamped close to 
the liver. A 30G needle was inserted into the duct from the 
duodenum through the ampulla of Vater, next the needle 
was clamped and 50 µl of virus were slowly injected 
(approximately 10 µl every 10 s). One minute later clamps 
were removed and the wound on the ampulla was closed 
with Histoacryl® (B.Braun). Abdominal muscle layer was 
closed with interrupted suture and the overlying skin was 
closed using Autoclips® (Stoelting Europe).
Bioluminescence assay and quantification of 
luciferase expression
In vivo and ex vivo luciferase activity was visualized 
and quantified using an in vivo bioluminescent system 
(IVIS50; Xenogen; Caliper Life Sciences) and Living 
Image 2.20.1 Software overlay on Igor Pro4.06A software 
(Wavematrics) as previously described [35]. Luciferase 
transgene expression in tissue extracts was quantified 
using the reporter Luciferase Assay System (Promega) as 
previously described [13]. 
Antitumoral efficacy
To evaluate the antitumoral capacity of 
AduPARTKT/GCV therapy, Ela-myc mice of 11 weeks of 
age were randomly divided in PBS (n=9), GCV (n=11), 
AduPARTKT (n=9), AduPARTKTHigh+GCV (n=9) and 
AduPARTKTLow+GCV (n=7) groups and were intraductally 
injected with 5x1010 vp or 1011 vp of AduPARTKT (Low 
and High, respectively). PBS and GCV groups received 
saline intraductally. AduPARTKT group received 1011 vp 
of AduPARTKT. Three days later, GCV treatment (100 mg/
Kg) was i.p administered for 6 days. Six weeks after virus 
administration, animals were sacrificed and the pancreas/
tumor was removed (Fig. 2D). Pancreatic volume was 
measured and calculated according to the following 
formula: V(mm3) = a × b × c /2, where a = length, b= 
width, c = height of pancreas.
To evaluate the antitumoral efficacy of ICOVIR15-
TKT, orthotopic PANC-1-Luc (n=8-10 per grup) and 
BxPC-3-Luc (n=8-9 per grup) pancreatic tumors were 
established. When tumors reached 106-107 photons/s 
measured by in vivo bioluminescence, which corresponds 
to approximately 100 mm3, animals were randomly 
divided into saline, ICOVIR-15, ICOVIR15-TKT 
and ICOVIR15-TKT+GCV, and were intraductally or 
intravenously injected with 5x1010 vp of the corresponding 
adenovirus. Three days later GCV (100 mg/Kg) treatment 
was initiated, according to the protocol described in 
Fig.3D. Tumor growth was monitored by bioluminescence 
analysis.  Survival studies were performed and animals 
were sacrificed according to ethical guidelines.
Immunohistochemistry 
Paraformaldehyde-fixed paraffin-embedded tissues 
and frozen tumor sections were prepared as previously 
described [29]. Five-micrometer paraffin-embedded 
sections were treated with 10 mM citrate buffer (pH 
6.0) for antigen retrieval and incubated overnight at 4°C 
with anti-luciferase (L0159, Sigma) or with anti-GFP 
(A6455, Invitrogene) antibodies. Bound antibodies were 
detected with LSAB+ system-HRP (K0679, Dako). Tissue 
sections were counterstained with Harris’s hematoxylin 
and mounted with EUKITT® (Sigma-Aldrich). Images 
were captured with a microscope (Leica DM6000 B) and 
digital camera (Leica DFC300 FX; Leica Microsystems) 
and processed with Leica Application Suite software. 
Immunofluorescence was performed in OCT-embedded 
sections by incubating with anti-adenovirus E1A (clone 
sc-430, Santa Cruz Biotechnology). Alexa Fluor 488 goat 
anti-rat antibody (Molecular Probes, Life Technologies™) 
was used as a secondary antibody. Nucleus were 
counterstained with 5 µg/ml bis-benzimide (Hoechst 
33342; Sigma) and visualized under a fluorescent 
microscope (Observer/Z1; Zeiss). The fluorescent images 
were captured using a digital camera (AxioCamMRm; 
Zeiss).
Pancreas toxicity study
Untreated 11-week-old Ela-myc mice or treated 
by intraductal injections of AduPARTKT (5x1010 vp) 
followed by six doses of GCV (daily dose of 100 mg/Kg) 
were used for toxicology. Blood samples were collected 
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at the indicated time-points. Serum amylase and lipase 
were determined on an Olympus AU400 Analyzer in the 
Clinical Biochemistry and Hematological Services of 
the Veterinary Faculty at the Autonomous University of 
Barcelona.
statistical analysis
Results are expressed as mean ± SEM of at least 
three independent experiments. Statistical differences 
were determined using Prism (version 5; GraphPad 
software) and were considered significant for P values 
less than 0.05. A Mann-Whitney nonparametric test 
was used for the statistical analysis (2-tailed) of in vitro 
studies. Regular two-way ANOVA was used to compare 
differences between the TK/GCV bystander effect in 
tumoral cell lines. Repeated-measures ANOVA was used 
to compare time-dependent differences among groups 
(pancreas toxicity study and ICOVIR15-TK tumor growth 
curves). Kruskal-Wallis test with Mann-Whitney U test 
for post hoc analyses was used to compare differences 
among AduPARTKT treatment groups. Survival studies 
were performed to analyze time-to-event probability. 
The survival curves (Kaplan-Meier curves) obtained 
were compared for the different treatments. Animals that 
were alive at the end of the experiment were included as 
right censored information. A log-rank test was used to 
determine the statistical significance of the differences in 
time-to-event. 
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